PD-1抑制剂治疗黑色素瘤中出现免疫相关皮肤不良事件与生存预后相关
该单中心队列研究纳入82例接受帕博利珠单抗或纳武利尤单抗治疗的IIIC-IV期黑色素瘤成人患者,随访中位40.7个月,33例出现至少1种目标皮肤反应。时依Cox模型显示,出现至少1种皮肤不良事件者疾病进展或死亡的风险比为0.46(95%CI 0.23-0.91;
要点
- PD-1抑制剂治疗中约三分之一患者在6个月内出现目标皮肤反应。
- 出现湿疹、苔藓样反应或白癜风样脱色者进展或死亡风险更低。
- 皮肤不良事件或可作为PD-1抑制剂疗效的预后标志。
核心结论
- 出现至少1种目标免疫相关皮肤不良事件与改善的无进展生存期相关。
研究设计与样本
- 单中心队列研究,纳入82例IIIC-IV期黑色素瘤成人患者,接受帕博利珠单抗或纳武利尤单抗治疗。
- 研究期间为2012年5月1日至2018年2月1日,地点为澳大利亚悉尼Westmead医院。
- 疗效评估基于iRECIST 1.1版。
主要发现
- 82例患者平均年龄59.9岁,中位随访40.7个月。
- 33例患者出现至少1种目标皮肤反应。
- 约三分之一患者在6个月内出现皮肤反应。
关键数值与推荐
- 目标免疫介导皮肤事件包括湿疹、苔藓样反应和白癜风样脱色。
临床怎么用
- 在PD-1抑制剂治疗黑色素瘤过程中,出现目标皮肤不良事件可能提示较好的预后。
局限性
- 单中心研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment response to new immunotherapy in advanced melanoma patients remains varied between individuals. Immune-related cutaneous side effects might have prognostic value. OBJECTIVE: To determine whether development of ≥1 of the 3 immune-mediated cutaneous events (eczema, lichenoid reaction, or vitiligo-like depigmentation) is associated with improved progression-free survival. METHODS: A cohort study of adults with stage IIIC-IV melanoma treated with pembrolizumab or nivolumab during May 1, 2012-February 1, 2018, at Westmead Hospital, Sydney, Australia. Treatment response was based on iRECIST version 1.1. RESULTS: In total, 82 patients of an average age of 59.9 years were included. Median follow-up was 40.7 months; 33 patients had ≥1 target skin reaction. Skin reactions developed in one-third of individuals by 6 months. At any given time, the instantaneous risk of disease progression and death was lower for individuals who had ≥1 cutaneous adverse event (CAE) develop. Compared with individuals with no CAE, the hazard ratio for disease progression and death for individuals who had ≥1 CAE develop was 0.46 (95% confidence interval 0.23-0.91; P = .025) by the time-dependent Cox proportional hazards model. LIMITATIONS: Single-center study. CONCLUSION: This study demonstrates an association between the development of ≥1 of 3 CAEs and improved progression-free survival in this cohort of patients.
引用
- Chan L, Hwang SJE, Byth K, et al. Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. J Am Acad Dermatol. 2019. PMID: 31233857. doi:10.1016/j.jaad.2019.06.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。